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Abstract
 
Gluten sensitivity typically presents as celiac disease, a common chronic small intestinal disor-
der. However, in certain individuals it is associated with dermatitis herpetiformis, a blistering
skin disease characterized by granular IgA deposits in the papillary dermis. While tissue trans-
glutaminase has been implicated as the major autoantigen of gluten sensitive disease, there has
been no explanation as to why this condition appears in two distinct forms. Here we show that
while sera from patients with either form of gluten sensitive disease react both with tissue trans-
glutaminase and the related enzyme epidermal (type 3) transglutaminase, antibodies in patients
having dermatitis herpetiformis show a markedly higher avidity for epidermal transglutaminase.
Further, these patients have an antibody population specific for this enzyme. We also show that
the IgA precipitates in the papillary dermis of patients with dermatitis herpetiformis, the defining
signs of the disease, contain epidermal transglutaminase, but not tissue transglutaminase or kera-
tinocyte transglutaminase. These findings demonstrate that epidermal transglutaminase, rather
than tissue transglutaminase, is the dominant autoantigen in dermatitis herpetiformis and ex-
plain why skin symptoms appear in a proportion of patients having gluten sensitive disease.
Key words: gluten sensitive enteropathy • celiac disease • IgA • immune complex • skin
 
Introduction
 
Gluten sensitive enteropathy (GSE)
 
*
 
 is evoked and main-
tained by gluten, the adhesive mass of water-insoluble pro-
teins found in many cereals. The clinical appearance of
GSE is typically celiac disease (CD), a common chronic
small bowel disorder; however, in certain individuals it is
associated with the skin disorder dermatitis herpetiformis
(DH). This is a bullous skin disease with polymorphic pap-
ules and blisters typically located over the extensor surfaces
of the major joints and characterized by granular IgA de-
posits in the papillary dermis. Gastroenterological symp-
toms in DH are generally mild or clinically completely ab-
sent (1), however, inflammatory small bowel changes can
often be found by histological examination even in the ab-
sence of clinical signs. The enteropathy in DH is morpho-
logically identical with that in CD suggesting identical or
very similar etiology and pathomechanism in both DH and
CD (1). Further, both occur in the same genetic back-
ground being primarily associated with the HLA class II
genes HLA-DQA1
 
*
 
0501, DQB1
 
*
 
02, and to a lesser extent
with the HLA-DQA1
 
*
 
03, DQB1
 
*
 
0302 genes (for a re-
view, see reference 2).
Both CD and DH patient sera show a typical IgA stain-
ing pattern when applied to tissue sections containing re-
ticulin fibers such as endomysium. Recently, tissue trans-
glutaminase (TGc, EC 2.3.2.13) was shown to be the
predominant autoantigen in these sections (3, 4) and ELISA
tests based upon this protein have been shown to be useful
for the diagnosis of GSE (5, 6, 7, 8). TGc is a member of
the transglutaminase (TG) family, which in man consists of
nine distinct proteins present in a wide variety of cell types
(Table I; references 9–27). TG family members show con-
servation especially of certain enzymatically relevant do-
mains (10, 19). The active members catalyze a posttransla-
tional modification linking low molecular weight amines to
proteins, or induce an isopeptide bond between or within
polypeptide chains leading to a cross-linked supramolecular
 
Address correspondence to Dr. M. Sárdy, Dept. of Dermato-Venere-
ology, Semmelweis University, H-1085 Budapest, Mária u. 41,
Hungary. Phone: 36-1-266-0465/5718; Fax: 36-1-267-6974; E-mail:
sardy@bor.sote.hu
 
*
 
Abbreviations used in this paper:
 
 AU, arbitrary unit(s); CD, celiac dis-
ease; CI, confidence interval; DH, dermatitis herpetiformis; EMA,
endomysium Ab; GSD, gluten sensitive disease; GSE, gluten sensi-
tive enteropathy; TG, transglutaminase; TGc, tissue (cellular, type 2)
transglutaminase; TGe, epidermal (type 3) transglutaminase; TGk, kerati-
nocyte (type 1) transglutaminase; TGx, type 5 transglutaminase. 
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protein network (for reviews, see references 9 and 11); fur-
ther, under special circumstances they are also able to deam-
idate glutamine residues.
The discovery of TGc as the main endomysial autoanti-
gen failed to explain why only a proportion of gluten sensi-
tive patients show symptoms of DH and whether there is a
difference in the antigenic repertoire between CD and
DH. By comparing the Ab responses to skin transglutami-
nases we could show that CD and DH are diseases where
the main autoantigens are distinct but share common
epitopes. This explains the similarities in pathology while
also clarifying why certain gluten sensitive patients present
with dermatological symptoms.
 
Materials and Methods
 
Mass spectrometry, SDS-PAGE, and endomysium Ab (EMA)
tests were performed as described previously (8).
 
Production of Recombinant Human Transglutaminases.
 
Human
TGc was expressed recombinantly in the human embryonic kid-
ney cell line 293-EBNA as a COOH-terminal fusion protein
with the eight amino acid Strep II tag, and purified via streptavi-
din affinity chromatography as described previously (8).
To express human epidermal (type 3) transglutaminase (TGe),
a method similar to that for TGc was used. Total RNA from hu-
man keratinocytes was reverse transcribed and the cDNA coding
for the TGe proenzyme amplified by PCR using the forward
primer 5
 
 
 
-ATTAAGCTTGCCGCCACCATGGCTGCTCTA-
GGAGTC, and the reverse primer 5
 
 
 
-ATTGCGGCCGCTT-
CGGCTACATCGATGGACAAC. The forward primer intro-
duced a HindIII restriction site and a Kozak translation initiation
sequence while the reverse primer inserted a NotI restriction site
and removed the stop codon. The PCR product was digested
with the HindIII/NotI restriction enzymes and inserted at the
same restriction sites into the episomal eukaryotic expression vec-
tor pCEP-Pu/TGc/C-Strep (8), producing pCEP-Pu/TGe/
C-Strep. The correct insertion and sequence of the full construct
 
Table I.
 
Comparison of Transglutaminases (References 9–27)
 
TG FXIIIa TGk TGc TGe TGp TGx TGy TGz Band 4.2
Gene name F13A1 TGM1 TGM2 TGM3 TGM4 TGM5 TGM6 TGM7 EPB42
Chromosomal
localization
6p24-25 14q11.2 20q11-12 20q11 3p21-22 15q15.2 20q11 15q15.2 15q15.2
Number of 
amino acids
without the
1. Methionine
731 816 686 692 683 719 706 709 690
Molecular
weight (kD)
 
 
 
77
 
 
 
106
 
 
 
78
 
 
 
77
 
 
 
77
 
 
 
81
 
 
 
79
 
 
 
80
 
 
 
72
Primary
molecular
features
Exists as zymogen
with 2
catalytic a subunits
and 2 b subunits
Exists as
zymogen,
both cytosolic
and
membrane
associated
Monomeric Exists as
zymogen
Monomeric Monomeric
(occurs as
splice
variants)
Unknown Unknown Monomeric,
lacks enzymic
activity
Presence in
the skin
(mRNA)
Yes Yes Yes Yes No Yes No? Yes Yes
Presence in
other cells,
tissues,
or organs
Blood plasma, platelets,
monocytes-macrophages,
hepatocytes,
chondrocytes,
placenta
Keratinocytes,
epithelial cells
in stratified
squamous
epithelia,
endometrium,
ducts of
pancreas and
mammary
glands
Widespread Mouse: brain,
stomach,
spleen,
small intestine,
esophagus,
testis,
skeletal
muscle,
Human: kidney
and lung.
Prostate
only
Widespread Unknown Widespread RBCs,
platelets,
fetal liver
and kidney,
adult brain,
adult kidney?
 
FXIIIa, factor XIII a-subunit; TGy, transglutaminase type 6; TGz, transglutaminase type 7; band 4.2, erythrocyte protein band 4.2; RBC, red blood cell.  
749
 
Sárdy et al.
was verified by cycle sequencing. The plasmid was electroporated
into human embryonic kidney cells (293-EBNA; Invitrogen) and
transfected cells were selected with puromycin. Expression of the
proenzyme, which has an additional COOH-terminal Strep II fu-
sion tag, was confirmed by immunoblotting using a rabbit poly-
clonal serum raised against the Strep II tag (IBA). The protein was
isolated by affinity chromatography using StrepTactin® (IBA) as
described previously (8, 28).
 
Transglutaminase Activity Assay.
 
TGe and TGc activity was
measured by incorporation of [1,4-
 
3
 
H]putrescine as described
previously (8). The TGe was activated by partial proteolytic di-
gestion preincubating it 20 min at 37
 
 
 
C together with either 45.4
 
 
 
g/ml (0.5 U/ml) proteinase K (Sigma-Aldrich), or 45.4 
 
 
 
g/ml
(55.4 U/ml) trypsin 1:250 (Sigma-Aldrich), or 1.18 mg/ml (1 U/ml)
dispase (Life Technologies).
 
Production of Rabbit Sera against Human TGe.
 
Rabbits were
immunized with the COOH-terminally tagged human TGe
proenzyme. TGe Abs were affinity purified by binding to Sepha-
rose 6B (Amersham Pharmacia Biotech) coupled TGe and tested
for cross-reactivity against TGc, keratinocyte TG (TGk), and fac-
tor XIII.
 
Sera and Patients.
 
All patients had been examined at the Gas-
troenterological Departments of Internal Medicine or Pediatrics
and the Department of Dermato-Venereology of Semmelweis Uni-
versity, Budapest. The diagnosis of CD was confirmed by EMA
positivity and jejunal biopsy while DH was proven by skin biopsy
using both conventional and immunohistochemical techniques.
Sera were obtained from 59 patients with DH (including 43 sam-
ples from untreated patients, and 16 from patients on a complete or
incomplete gluten-free diet) and 104 with CD (including 36 sam-
ples from untreated patients, and 68 from patients on a complete or
incomplete gluten-free diet). Sera from 79 patients with non-CD
gastrointestinal diseases, 47 with other diagnoses, and 30 from
healthy individuals including 20 healthy relatives of CD patients
were also included. Mean ages and sex ratios of the patients are de-
tailed in Table II. No individual in this study had IgA deficiency.
All serum samples were stored at 
 
 
 
78
 
 
 
C until assayed.
 
TGe and TGc ELISAs.
 
The ELISA method was as for the
human TGc and described previously (8). Briefly: 96-well micro-
titer plates (MaxiSorp; Nunc) were coated with 1 
 
 
 
g per well of
either human TGc or TGe in 100 
 
 
 
l of 50 mM Tris/HCl (pH
7.5) containing 5 mM CaCl
 
2
 
 at 4
 
 
 
C overnight (at least 9 h). No
blocking was used. After each step the wells were washed by 50
mM Tris/HCl (pH 7.5) containing 10 mM EDTA and 0.1%
Tween 20 (TET). Sera were diluted to various concentrations
with TET, and incubated on the plates for 1.5 h at room temper-
ature. Bound IgA was detected by peroxidase-conjugated Ab
against human IgA (Dako), diluted 1:4,000 in TET, and incu-
bated for 1 h at room temperature. The color was developed by
100 
 
 
 
l of 60 
 
 
 
g/ml 3,3
 
 
 
,5,5
 
 
 
-tetramethylbenzidine substrate in
100 mM sodium acetate (pH 6.0) containing 0.015% H
 
2
 
O
 
2
 
 at
room temperature. The reaction was stopped by adding 100 
 
 
 
l of
20% H
 
2
 
SO
 
4
 
. For the TGc, the color reaction was always stopped
after 5 min; for the TGe, it was stopped after 15–20 min accord-
ing to kinetic measurements so that the OD of the standard se-
rum reached at least 0.6, but did not exceed 1.1. The absorbance
was read in an ELISA reader at 450 nm. All serum samples were
examined in triplicate, and triplicates of a negative and two posi-
tive reference sera were included in each assay. The Ab concen-
trations were expressed in arbitrary units (AU), i.e., as percent-
ages of one of the positive reference sera. To semiquantitatively
compare the IgA levels measured in the TGc and TGe ELISA as-
says, the standard serum was assayed in an identical manner
against wells coated either with TGe or TGc. These were com-
pared with standardized amounts of human IgA (Sigma-Aldrich).
The protein coating efficiency of the ELISA plates was first deter-
mined by BCA protein quantification (Pierce Chemical Co.).
 
Inhibition ELISA.
 
The ELISA method was as described
above, but before their addition to the coated ELISA plate, the
test sera were diluted to a fixed concentration and incubated with
a dilution series of TGc or TGe. Sera and protein were mixed to-
gether for 90 min in a shaking incubator at 37
 
 
 
C. The fixed se-
rum dilution was chosen in each case to obtain the greatest OD
difference between the IgA Ab titers of the sera with and without
 
Table II.
 
The Patients’ Number, Sex, Age at the Time of Blood Sampling, and Serum Ab Concentrations Against TGc and TGe
 
Median Ab cc. against
TGc (in AU)
Median Ab cc. against
TGe (in AU)
Diagnosis
No. of
patients
Male/
female
Mean age (yr)
(min.–max.) Median 95% CI Median 95% CI
CD 104 40/64 12.5 (0.9–66) — — — —
CD, untreated 36 12/24 17.8 (1.4–66) 88.1 68.2–98.1 65.8 47.6–96.1
CD, on a GFD 68 28/40 9.7 (0.9–34.3) 22.7 16.6–41.0 20.3 15.2–26.6
DH 59 31/28 30.8 (6.2–73.5) — — — —
DH, untreated 43 23/20 32.8 (6.2–73.5) 63.3 54.8–77.6 70.1 54.6–75.7
DH, on a GFD 16 8/8 25.6 (10.3–45) 24.3 18.0–68.1 27.8 21.3–43.6
Controls 156 75/81 10.2 (0.5–55.5) 11.1 10.7–11.7 13.6 12.6–14.7
GI diseases 79 40/39 5.4 (0.5–27.6) 11.0 10.4–11.4 12.6 10.4–14.4
Other diagnoses 47 22/25 11.0 (0.7–53.2) 11.2 10.3–12.5 13.6 12.8–14.9
Healthy individuals 30 13/17 21.9 (0.7–55.5) 13.0 9.8–14.7 15.4 13.6–18.4
All samples 319 146/173 14.8 (0.5–73.5) — — — —
cc., concentrations; GFD, gluten-free diet; GI, gastrointestinal. 
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preincubation (1:500–1:4,000 for inhibition of the TGc ELISA,
1:125–1:1,000 for the TGe ELISA). These diluted sera were then
incubated with a dilution series containing different amounts of
TGc or TGe in 160 
 
 
 
l TET. The color reaction was stopped at 5
min for the TGc-coated ELISA and 15 min for the TGe ELISA.
 
Affinity Purification of Patient Abs Directed Exclusively against
TGe.
 
TGc or TGe was coupled to CNBr activated Sepharose
4B, 50 
 
 
 
g of coupled protein per patient sample was used in the
purifications described below. 80 
 
 
 
l of serum was diluted 1:10
with 10 mM Tris (pH 7.5) and was circulated over a TGc col-
umn for 1 h. For a number of high titer samples the efficiency of
anti-TGc Ab depletion was assayed at this step. To obtain TGe
specific Abs and remove any traces of TGc immunoreactivity, the
flow through now depleted of TGc reacting Abs was then ap-
plied to a TGe column in the same manner. The TGe columns
were washed with 250 
 
 
 
l of 10 mM Tris (pH 7.5) followed by
250 
 
 
 
l of 10 mM Tris, (pH 7.5) containing 0.5 M NaCl. Bound
Abs were eluted with 250 
 
 
 
l 100 mM glycine (pH 2.5) or 250 
 
 
 
l
100 mM triethylamine (pH 11.5) directly into 250 
 
 
 
l 1 M Tris
(pH 8.8). These solutions were then dialyzed against PBS (pH
7.4). The Abs eluted from the TGe column were tested in the
TGc and TGe ELISAs as described above.
 
Direct Immunofluorescence.
 
6-
 
 
 
m cryostat tissue sections of hu-
man jejunal biopsy samples, human skin, or the aboral part of
monkey esophagus were used for staining. Bound IgA was de-
tected by 
 
 
 
-chain specific, affinity purified, FITC-conjugated,
goat anti–human IgA Abs (Sigma-Aldrich) at a dilution of 1:100
in phosphate-buffered saline (PBS, pH 7.4).
For localization of TGe, the affinity purified rabbit antisera
raised against the recombinant TGe proenzyme was diluted 1:100
in PBS, followed by incubation with Cy3-labeled goat antisera
raised against rabbit immunoglobulins (Sigma-Aldrich), diluted
1:800 in PBS. For TGc and TGk, mouse mAbs (Neomarkers,
Ab-3 [a mix of mAbs CUB7402 and TG100], and Biomedical
Technologies, mAb BC.1, respectively) were diluted 1:100 and
1:50 in PBS followed by incubation with Cy3- or FITC-labeled
sheep anti–mouse Abs diluted 1:800 or 1:400, respectively.
 
Statistics.
 
The optical densities (and thus titers given in AU
values) had Gaussian distribution neither in the control group nor
among CD or DH patients, thus for description of Ab concentra-
tions, medians with their 95% confidence intervals (95% CI) are
presented (29). For description and comparison of the two ELISA
systems, the areas under the receiver operating characteristic
curves are given. For comparison between patient groups, Mann-
Whitney’s nonparametric, unpaired, two-tailed test is shown
(30). To describe the correlation of titers, the Spearman’s correla-
tion coefficient with its 95% CI and correlation analysis for un-
paired data of nonnormal distribution was used (29, 30). For
comparison of the TGc and TGe Ab inhibition assays, Wil-
coxon’s two-tailed signed rank test for pairs was performed (30).
 
Results
 
Production and Purification of Recombinant TGe
 
The human TGe was expressed in the 293-EBNA hu-
man embryonic kidney cell line as a fusion proenzyme with
the Strep II tag. The protein was purified in a single step,
and eluted as one 80 kD band when visualized by Coo-
massie-staining after SDS-PAGE (Fig. 1). The molecular
mass calculated for the tagged human TGe proenzyme is
78.0 kD (the COOH-terminal tag having a mass of 1.2
kD). Although the recombinant human TGc and TGe
have approximately the same calculated molecular mass
(78.4 kD for TGc), the human TGc migrated slower than
expected when visualized by SDS-PAGE (8; Fig. 1). Mass
spectrometry of the TGe fusion protein gave a molecular
mass of 77.8 kD. The yield from the lysate of a confluent
cell monolayer in a cell culture dish of 13 cm diameter was
 
 
 
100 
 
 
 
g of purified protein. In cell lysates, the activity of
the recombinant human TGe was 2.5 times higher than the
background activity of transglutaminases present in un-
transfected 293-EBNA cells. The freshly purified human
TGe proenzyme showed 
 
 
 
2% of the activity of the same
amount of human TGc. The human TGe activated with
different proteases (proteinase K, trypsin, or dispase)
showed similar or higher activity than the TGc, which is
similar or higher than the activity of the commercially
available guinea pig TGc enzyme (Sigma-Aldrich).
 
CD and DH Patient Sera Contain IgA Abs against TGe and TGc
 
We have previously described a TGc ELISA based upon
the human recombinant protein (8), ELISAs were per-
formed against TGe or TGc using the same antigen con-
centration for coating, serum dilution, and positive and
negative reference sera. As signals in the TGe ELISAs were
for every serum significantly lower than against TGc, color
development in the TGe ELISA was allowed to continue
3–4 times longer than that in the TGc ELISA until the pos-
itive reference serum reached similar ODs in both ELISAs.
The results are expressed as a percentage (AU) of the signal
of the positive reference serum in both assays. These ELISA
results show that patients with both DH and CD have se-
rum IgA Abs reacting against TGe and TGc (Fig. 2). To al-
low a comparison of the levels of IgA directed against ei-
ther TGc or TGe, the reference serum (100 AU in the
above assays) was assayed under identical conditions upon
Figure 1. SDS-PAGE analysis of TGc
and TGe after purification. Positions of
molecular mass standards (kD) are indi-
cated on the left. Arrows show the start
and end lines of the gel. 
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TGe and TGc coated ELISA wells in parallel to wells
coated with a known amount of IgA. The anti-TGc IgA
signal corresponded to 16.78 
 
 
 
g/ml of serum while the
concentration of anti-TGe IgA in the positive reference se-
rum was 2.45 
 
 
 
g/ml. In the TGe ELISA, the mean intra-
and interassay coefficients of variation for the positive stan-
dard serum used for AU calculation were 2.7 and 19.1%,
respectively. The mean intra- and interassay coefficients of
variation (using Ab concentrations given in AU) for the
other sera tested in the human TGe ELISA were 4.7% (
 
n
 
 
 
 
 
334) and 16.4% (
 
n
 
 
 
  
 
74), respectively.
The median Ab concentrations (in AUs) from the TGe
and TGc ELISAs with their 95% CIs are presented in Ta-
ble II. Although the confidence intervals overlapped, the
median Ab concentration against TGc was significantly
higher in CD than in DH patients (
 
P
 
 
 
  
 
0.0188). How-
ever, there was no significant difference in the Ab levels
against TGe between CD and DH patients. The median
Ab concentrations against TGc and TGe were significantly
higher in untreated CD or DH patients when compared
with the controls (
 
P
 
 
 
  
 
0.0001 in each case). Differences
between the control subgroups were not significant. Both
CD and DH patients had reduced Ab activity against TGe
when on a gluten-free diet, results similar to those ob-
served for TGc Abs.
The two ELISAs showed good linear correlation (r
 
S 
 
 
 
0.851, 95% CI: 0.818–0.878, 
 
P
 
 
 
  
 
0.0001, data not shown).
Indeed, the human TGe ELISA seemed to be suitable for
diagnosis of GSE. The area under the receiver operating
characteristic curve was 0.982 (in the TGc ELISA it was
0.997). In the TGe ELISA, a cutoff value of 23.7 AU, cho-
sen based upon the analysis of the receiver operating char-
acteristic curve, gave a specificity and a sensitivity of 92.3%
(95% CI: 88.9–95.7%) and 92.4% (95% CI: 89–95.8%), re-
spectively. The coincidence of the human TGe assay with
the clinical diagnosis of CD or DH was 217/235 (92.3%),
giving 12 false-positive and 6 false-negative results (Fig. 2
B). Four of the false-negative patients had DH, two of
them were EMA negative. All the other DH or CD pa-
tients were positive for EMA.
For comparison, the TGc ELISA using a cut-off value of
18 AU (8) gave in this study a specificity and a sensitivity of
94.2% (95% CI: 91.2–97.2%) and 98.7% (95% CI: 97.2–
100%), respectively. The coincidence of the human TGc
assay with the clinical diagnosis was 225/235 (95.7%), giv-
ing one false-negative and nine false-positive results (Fig. 2
A). The false-negative serum and three of the false-positive
sera were also falsely detected in the TGe ELISA.
These results suggest that either GSE patients have Abs
cross-reacting between different transglutaminases or that
specific Abs against both TGc and TGe occur in GSE and
that Abs directed against TGe, as those against TGc, are
maintained by the ingestion of gluten.
 
Inhibition ELISAs Show Differences in Ab Avidity to TGe 
between DH and CD Patients
 
To discover the significance of Ab cross-reactivity be-
tween these enzymes within the two patient groups, we
performed inhibition studies. ELISA plates were coated
with either human TGc or TGe, and the patient sera were
preincubated with various concentrations of either of the
two transglutaminases. Initial experiments allowed us to
find appropriate serum dilutions giving results within a lin-
ear range for the given ELISA. The degree of inhibition
produced by the preincubation with either of the two pro-
teins was compared with control samples where the sera
had been preincubated with buffer alone. The results are
presented as reduction in the optical density given as per-
centage of the controls. Two examples of these inhibition
ELISAs performed over a range of inhibitor concentrations
with typical CD and DH sera are shown in Fig. 3. For
group analysis of 36 CD and 34 DH patients, results of in-
hibition with 32 ng and 1 
 
 
 
g of the relevant transglutami-
nase are shown in Fig. 4.
 
Inhibition of Abs against TGc.
 
We analyzed 34 sera of
DH patients and 36 CD patients. The sera were diluted as
described above and preincubated with human TGc or TGe
Figure 2. Analysis of serum anti-TGe and anti-TGc IgA. Serum con-
centrations of IgA Abs (in AU) against human TGc (A) and TGe (B) in
healthy individuals (H), other controls (CTRL), patients having untreated
CD or DH, as well as those on a complete or incomplete gluten-free diet
(CDG and DHG, respectively). 100 AU corresponds to 16.78  g IgA/ml
of serum in the TGc ELISA and 2.45  g IgA/ml in the TGe ELISA. 
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in various concentrations before addition to ELISA wells
coated with TGc. While incubation with even such low
amounts as 32 ng of TGc (always in a volume of 160 
 
 
 
l, see
Materials and Methods for details) effectively inhibited the
reactivity of the sera from both the DH and CD patients
with the coated TGc, the TGe failed to block the TGc re-
activity (Fig. 3, A and B). Only at very high concentrations
(above 10 
 
 
 
g) did preincubation with TGe produce any in-
hibition in the TGc ELISA (data not shown). There was no
significant difference in the inhibition when comparing the
results from DH or CD patient groups in these experiments.
 
Inhibition of Abs against TGe.
 
Sera from DH and CD
patients were diluted to the chosen dilution and preincu-
bated with TGc or TGe before addition to ELISA wells
coated with TGe. Here the human TGe, at 32 ng, effec-
tively inhibited the reactivity of sera from DH patients with
human TGe (Figs. 3 D and 4), but failed to inhibit that
from CD patients (Figs. 3 C and 4). At higher concentra-
tions, the inhibitory effect of preincubation with TGe in-
creased with sera from DH patients and also a slight inhibi-
tion of the reactivity of sera from CD patients occurred
which was more apparent upon the addition of very high
amounts of TGe (up to 8 
 
 
 
g, results not shown). The dif-
ference between CD and DH patient groups upon inhibi-
tion with TGe was highly significant (
 
P
 
 
 
  
 
0.0001; Fig. 4).
At low concentrations, the human TGc produced only
very marginal inhibition. However, when at high concen-
trations (at or above 1 
 
 
 
g), it could inhibit the reactivity of
IgA Abs to TGe in both disease groups (Fig. 3, C–D, and
Figure 3. Transglutaminase inhibition
ELISAs, typical examples of inhibition
curves. Each diagram shows the effect of
preincubation on the remaining IgA Ab re-
activity in one single serum sample from a
patient with untreated CD (A and C) or
DH (B and D). On the vertical axis is the
remaining IgA Ab reactivity against TGc (A
and B) or TGe (C and D) given in percent-
age of the buffer control, on the horizontal
axis are inhibitor amounts on a logarithmic
scale used for preincubation. The control
was preincubated with buffer only, the
other samples with a serial dilution of TGc
(continuous line) or TGe (dashed line). The
TGe is seen to be an effective inhibitor of
IgA Abs against TGe only in DH patients
(D), but not in individuals with CD (C) (see
group analysis in Fig. 4, statistics in the
text). TGc has the greatest inhibitory effect
on IgA Abs against TGc in CD patients (A).
 
Figure 4.
 
Effect of preincubation of sera from patients with CD (
 
n
 
 
 
  
 
36)
or DH (
 
n
 
 
 
  
 
34). On the vertical axis, remaining IgA Ab reactivity against
TGe is indicated in percentage of the buffer control. The four dot diagrams
on the left show the inhibitory effect of preincubation with 32 ng of TGc
(c) or TGe (e) on the remaining IgA Ab reactivity of sera from patients
with CD and DH. The four dot diagrams on the right demonstrate the
same using 1 
 
 
 
g of TGc or TGe for preincubation. The asterisks on top of
connecting lines show the degree of significance in the difference between
the two groups of samples so linked: 
 
*
 
P 
 
  
 
0.05; 
 
**
 
P 
 
  
 
0.01; 
 
***
 
P 
 
  
 
0.001. 
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Fig. 4), although CD sera were more strongly inhibited
than DH sera (
 
P
 
 
 
  
 
0.0054). These results provide evidence
of various IgA Ab populations directed against both com-
mon and different epitopes on the two molecules and sug-
gest that in DH patients there are IgA Abs with a high
avidity directed against TGe.
 
Purification of TGe Abs from DH Sera
 
To discover if there are Ab populations exclusively di-
rected against TGe present in either DH or CD patients,
we affinity purified TGe specific Abs from patient sera.
Sera from 20 CD patients and 18 DH patients were applied
to columns of Sepharose 4B to which TGc had been co-
valently coupled. To test the efficiency of the removal of
TGc Abs from the sera, the flow through fractions from
this column were compared with a dilution series of the
starting sera. This was performed for a number of high titer
sera and showed a reduction of the TGc titer by some 98–
99%. To isolate anti-TGe IgA, the immunodepleted (flow
through) fraction was applied to columns carrying TGe,
and after washing, the Abs binding to TGe were eluted.
The eluates were compared with the unprocessed, precol-
umn sera for anti-TGe and anti-TGc immunoreactivity in
the relevant ELISAs.
The removal of TGc immunoreactivity was highly effec-
tive with the eluates from the TGe column showing little
or no reactivity in the TGc ELISA (Fig. 5). In the TGe
ELISA, however, the eluates from DH patients showed in
almost all cases significant levels of TGe immunoreactivity,
while those of CD patients generally failed to give a signal
(Fig. 5) displaying clear evidence for the existence of a
TGe-specific Ab population which is usually present in
DH but absent from the vast majority of CD patients.
 
TGe Is Present within the IgA Precipitates in DH Skin
 
The antigenic component of the granular IgA precipi-
tates occurring in the skin of DH patients was investigated
for the presence of transglutaminases. A rabbit antiserum
directed against the tagged human recombinant TGe
proenzyme was produced and the specificity of the purified
antiserum was verified in ELISA and immunoblots. This
serum gave no cross-reaction with human TGk or factor
XIIIa and a slight reactivity to human TGc, which was ap-
proximately a 100-fold lower than that to TGe. In normal
human skin, the anti-TGe Ab stained solely the epidermis
in a tapering manner being most intensive in the upper ke-
ratinocyte layers and quite different to the expression seen
for TGc (results not shown). In addition to the epidermal
signals, identical to those seen in normal skin, immu-
nostaining of the skin from 8 DH patients with this antise-
rum revealed that TGe is found in aggregates within the
dermal papillae (Fig. 6, A and C). This staining could be
blocked efficiently by preincubation of the sera with TGe
but not TGc or TGk (results not shown). Dual staining for
the presence of IgA showed that TGe and IgA colocalized
within these precipitates (Fig. 6 A) while TGc and TGk
were absent from the aggregates and had the expression
pattern seen in normal skin (TGc: Fig. 6 C; TGk: not
shown). To verify that an alteration in the TGe staining
pattern is a specific finding for DH skin, skin from patients
suffering from linear IgA dermatosis was also analyzed. In
this disease, IgA also accumulates within the skin but binds
to the dermo-epidermal basement membrane. Here no
TGe staining of the dermis or at the basement membrane
was found and no colocalization with the IgA signal oc-
curred (Fig. 6 B). Hence the IgA precipitates found in DH
are immunocomplexes containing TGe which accumulate
specifically in this disease.
 
Discussion
 
CD and DH are closely related diseases both induced by
a sensitivity to gluten. As they share an identical jejunal pa-
thology, genetic background, similar pathomechanism,
common diagnostic analysis, and shared dietary possibilities
for therapy, we suggest the term “gluten sensitive disease”
(GSD) for both of these forms of condition showing mani-
festation on gluten challenge, disappearance of symptoms
on gluten withdrawal, and recurrence of disease upon glu-
ten intake. Both forms of GSD can be subdivided into clin-
ical manifestations of different severity, as they can also
present with unspecific or even absent clinical signs or
symptoms. Moreover, epidemiological studies show that
the majority of GSD patients actually have very mild or
atypical symptoms or often clinically silent disease (31).
GSD is the result of three processes culminating in the in-
testinal mucosal damage of CD and in the skin defects of
DH. Both are hereditable conditions with strong associa-
Figure 5. Affinity purification of the Ab population directed against
TGe. Sera from CD and DH patients were circulated over columns of
Sepharose 4B to which TGc had been covalently coupled. The immu-
nodepleted fraction was then applied to columns carrying TGe. Unpro-
cessed serum samples (S) and eluates from the washed TGe column (El)
were compared for TGe and TGc immunoreactivity. The depletion
worked with high efficiency and there was little or no reactivity in the
TGc ELISA. In the TGe ELISA, the eluates from DH patients showed
significant levels of TGe immunoreactivity, while those of CD patients
generally failed to give a signal. Hence patients with DH have significant
levels of Abs directed specifically against TGe which do not cross react
with TGc, these Abs are absent in CD. 
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tions to identical HLA haplotypes; however, it does not ap-
pear that genetic factors alone decide the clinical outcome as
monozygotic twins may exhibit any combination of mani-
fest CD, DH, or clinically silent GSD (1, 32) proving envi-
ronmental factors are also significant. The main environ-
mental factor in GSD is the ingestion of gluten in cereals,
however, Abs against these proteins are not perfect diagnos-
tic markers for the disease and are found in a range of other
Figure 6. Colocalization of IgA and TGe in the papillary dermis of DH patients. (A) In DH patients, TGe shows normal distribution pattern in the
epidermis; typical precipitates are present, however, in the upper dermis. In these precipitates, the TGe (red) and the IgA (green) colocalize as visualized
with a confocal microscope (yellow). (B) The TGe precipitates are absent in linear IgA dermatosis, a bullous skin disease with linear IgA precipitates in
the upper dermis, suggesting that TGe deposits are specific markers for DH. In addition, this also demonstrates the absence of cross-reactivity of anti-TGe
Abs with IgA. (C) The TGe (and the IgA, data not shown) precipitates do not colocalize with TGc. 
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gastrointestinal disorders without any evidence that they play
a pathogenic role in these conditions (33, 34). However, the
third factor, namely that the patients’ immune system pro-
duces Abs reacting with the endomysium, is found present
in every form of GSD and is highly specific (35). The stan-
dard serological diagnosis for GSD depends upon the stain-
ing of endomysial tissue with IgA Abs, and it was shown that
the antigen within these sections is TGc (3, 6, 7, 36, 37).
The presence of autoantibodies to TGc has been shown to
be linked to disease activity with the titer decreasing when
patients are placed upon a gluten free diet and increasing
upon subsequent gluten challenge (6, 7). Our aim was to
understand why GSD appears as two distinct clinical entities.
Our initial hypothesis was that there was immunoreactiv-
ity specifically in the DH patient population against a fur-
ther transglutaminase expressed in the skin. Four trans-
glutaminases have been isolated from the skin, TGe and
TGk are both produced by epidermal cells, as is TGc,
which is also found together with factor XIIIa in the dermis.
To discover if any of these proteins are antigens in DH we
produced ELISAs based upon human transglutaminases. Ini-
tial ELISA studies using human recombinant TGk as well as
the commercially available human factor XIIIa showed that
there was no specific immunoreactivity in either CD or DH
patient sera against these enzymes (results not shown).
However, both patient groups had Abs recognizing TGe as
well as TGc. The results from the TGc and TGe ELISAs
showed a good correlation and indeed the specificity and
sensitivity of the TGe ELISA came close to that of the TGc
based test. However, in CD patients, the median Ab con-
centration against TGc was higher than against TGe, and
this was reversed for DH patients (Table II), although be-
cause of the overlapping confidence intervals this tendency
cannot be judged to be a true distinction. Further, the im-
munoreactivity for both proteins and in both disease groups
showed a reduction in titer when the patients were placed
upon a gluten free diet. This is in agreement with known
clinical improvement seen in DH patients on a gluten free
diet and the common background of both diseases.
Members of the transglutaminase family share a high de-
gree of sequence conservation especially in their active
sites. In the case of the TGe and TGc there is an overall
conservation of 38% at the amino acid level, but with up to
64% homology in certain regions (19). Phylogenetically,
TGe and TGc seem to be more related to each other than
to TGk or factor XIIIa (10). Cross-reacting Abs against
TGc or TGe in GSD patients are therefore not surprising;
however, we could use ELISA blocking experiments to
show differences in avidity for the different TGs between
the two patients groups. As expected, TGc inhibited the
reactivity of the sera from both CD and DH patients in the
TGc ELISAs showing that anti-TGc immunoglobulin spe-
cies are present in both diseases. In the TGe ELISA, how-
ever, inhibition with TGe could be invoked only in DH
patient sera suggesting the presence of high affinity anti-
TGe Abs in DH, and the presence of only of low affinity
TGe reactive Abs in CD. Recently three new members of
the TG gene family, type 5 transglutaminase (TGx), TGy,
and TGz (Table I), have been described (10). We were un-
able to test these transglutaminases in our study, thus the
possibility of cross-reactivity with other TGs cannot be
completely excluded.
Our results prove the presence of two Ab populations in
GSD, one against only TGe (detected in patients with DH
only, see Fig. 5), and one directed against common
epitopes of TGe and TGc (detected in both CD and DH,
see Fig. 4). A third population against only TGc may also
be present, but was not investigated. As shown by the dif-
ferences in the IgA levels against TGc and TGe in the stan-
dard serum, the concentration of IgA Abs directed against
epitopes present on TGe is much lower than that directed
against TGc. This means that both in DH and CD patients,
only a fraction of the Abs directed primarily against TGc
have cross-reactivity with TGe. In addition, DH patients
develop a higher avidity Ab population directed against
only TGe. This Ab fraction also is much smaller than that
against TGc. This explains why there is no apparent differ-
ence between sera of CD or DH patient groups in either
the TGc or TGe ELISAs (Fig. 2, A and B) and why the
TGc and TGe ELISA results from patient sera correlate.
While the Ab population directed against only TGe (found
in DH patients and having high avidity), can be inhibited
with very small amounts of TGe, those primarily directed
against TGc, (having low avidity against TGe) can only be
inhibited with high amounts of TGe. Accordingly in DH
patients typically a two-step inhibition curve is seen (Fig. 3
D). This further explains why preincubation of CD serum
(which has little or no high avidity TGe Abs) with TGc has
a greater impact on reactivity to TGe than preincubation
with TGe itself (Fig. 3 C).
While affinity purification of sera of GSD patients
showed that the presence of TGe-specific IgA is a hallmark
of DH rather than CD, a small number of patients (10%)
deviated from the bulk of results in both the blocking assay
and in their behavior upon purification. These DH pa-
tients, having Ab response characteristic for CD, might
currently be showing transition from CD into DH. The
CD patients, behaving rather as expected for DH patients,
might be expected in later life to show symptoms of DH, if
they continue gluten intake.
The diagnosis of DH depends upon the finding of IgA
deposits within the dermal papillae, and in the majority of
patients EMAs can also be detected (38). The latter is typi-
cally shown with the labeling of the endomysium, which
has earlier been shown to colocalize with the TGc staining
pattern (6, 37). Our observation that the major Ab popula-
tion both in CD and in DH is directed against TGc, sup-
ports the finding that the endomysial signal seen on mon-
key esophagus is of TGc origin and indeed we found that
TGe was present only in the epithelial cells of monkey
esophagus, but not in the endomysium (results not shown).
The epidermal staining pattern with the TGe antiserum
supported previous reports on its distribution (39), TGe
being present in the epidermis in a tapering manner, with
maximum staining of the upper epidermal layers. It was
also found present in hair follicles. In DH skin, the epider- 
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mal and hair follicle staining was indistinguishable from that
seen in normal skin, but the dermal IgA containing aggre-
gates also stained strongly for TGe. TGc, which was found
present in the basal keratinocytes, was absent from these ag-
gregates.
Our hypothesis for the etiology and pathogenesis of DH
is that TGc-gluten complexes initiate an IgA autoantibody
response (40), but fail to produce high affinity anti-TGc
immunoglobulins, so resulting initially in a silent CD.
These Abs cross react with TGe, but are of low avidity to
it. After prolonged gliadin provocation (DH patients usu-
ally show symptoms later in life than CD patients), specific
cross-reacting Ab populations develop in patients who will
go on to acquire DH. These Abs have a low affinity to
TGc, but extremely high affinity to TGe. Whether they
arise against TGe as a primary antigen or are the result of
epitope spreading cannot be answered at the moment.
Why only a proportion of patients develop specific Abs
against TGe and why these patients show only a very mild
form of enteropathy also remains to be elucidated.
We speculate that the skin pathology may be evoked by
the dermal deposition of circulating immune complexes
containing IgA and TGe. Possibly the TGe is active, result-
ing in covalent cross-linking of the complex to certain der-
mal structural elements. This could be the basis for the sta-
bility of these immune complexes, as it is known that the
IgA deposits in DH skin stay detectable up to a decade after
the introduction of a completely gluten-free diet (1). It
would also explain why it has not been possible to extract
the IgA immune complexes from the skin of DH patients.
Inflammation of the skin might eliminate the covalently
bound immune complexes. Indeed often the IgA granules
are present perilesionally but not in areas of blister forma-
tion. This circulating immune complex hypothesis for DH
is supported by a number of findings. First, TGe is ex-
pressed in several tissues in the body (Table I), and thus the
antigen might originate from organs other than the skin.
We failed to detect TGe in the human jejunum with our
rabbit antiserum (results not shown), although the mRNA
for the TGe proenzyme was demonstrated in mouse jejunal
tissue extracts (17). We did, however, detect TGe mRNA
in other human organs including the kidney (results not
shown). Further, the skin histology in DH has features in
common with other dermatoses induced by circulating im-
mune complexes (41), and although the main site of im-
mune complex deposition is the upper dermis, they are also
present in vessel walls. In DH, asymptomatic IgA immune
complex depositions can be detected in the kidney (42), a
situation often seen in systemic diseases caused by circulat-
ing immune complexes, and indeed DH-associated IgA
nephropathy has been reported (43). The fact that Abs in
DH sera do not bind to the normal human papillary dermis
again suggests that the deposits derive from circulating im-
mune complexes. The factors that induce the classical dis-
tribution pattern of skin lesions in DH patients, localized
mainly on extensor aspects, are as yet unknown. Here,
however, we have shown that high affinity anti-TGe IgA
maintained by gluten is present in DH patients and not in
patients suffering from CD and that TGe is present in the
skin IgA aggregates typical of DH.
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